Search our database by keyword

- or -

Examples

  • Search this entire website. Enter identifiers, names or keywords for genes, pathways, authors, ontology terms, etc. (e.g. eve, embryo, zen, allele)
  • Use OR to search for either of two terms (e.g. fly OR drosophila) or quotation marks to search for phrases (e.g. "dna binding").
  • Boolean search syntax is supported: e.g. dros* for partial matches or fly AND NOT embryo to exclude a term

Search results 3401 to 3500 out of 44733 for *

Category restricted to GOTerm (x)

<< First    < Previous  |  Next >    Last >>
0.018s

Categories

Category: GOTerm
« show all
Type Details Score
GO Term
GO:0001781 | neutrophil apoptotic process
Description: Any apoptotic process in a neutrophil, any of the immature or mature forms of a granular leukocyte that in its mature form has a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.
•
•
•
•
•
GO Term
GO:0006925 | inflammatory cell apoptotic process
Description: Any apoptotic process in an inflammatory cell, any cell participating in the inflammatory response to a foreign substance e.g. neutrophil, macrophage.
•
•
•
•
•
GO Term
GO:0033028 | myeloid cell apoptotic process
Description: Any apoptotic process in a myeloid cell, a cell of the monocyte, granulocyte, mast cell, megakaryocyte, or erythroid lineage.
•
•
•
•
•
GO Term
GO:0001782 | B cell homeostasis
Description: The process of regulating the proliferation and elimination of B cells such that the total number of B cells within a whole or part of an organism is stable over time in the absence of an outside stimulus.
•
•
•
•
•
GO Term
GO:0070227 | lymphocyte apoptotic process
Description: Any apoptotic process in a lymphocyte, a leukocyte commonly found in the blood and lymph that has the characteristics of a large nucleus, a neutral staining cytoplasm, and prominent heterochromatin.
•
•
•
•
•
GO Term
GO:0001783 | B cell apoptotic process
Description: Any apoptotic process in a B cell, a lymphocyte of B lineage with the phenotype CD19-positive and capable of B cell mediated immunity.
•
•
•
•
•
GO Term
GO:0045309 | protein phosphorylated amino acid binding
Description: Interacting selectively and non-covalently with a phosphorylated amino acid residue within a protein.
•
•
•
•
•
GO Term
GO:0051219 | phosphoprotein binding
Description: Interacting selectively and non-covalently with a phosphorylated protein.
•
•
•
•
•
GO Term
GO:0001785 | prostaglandin J receptor activity
Description: Combining with prostaglandin J (PGJ(2)), a metabolite of prostaglandin D (PGD(2)) to initiate a change in cell activity.
•
•
•
•
•
GO Term
GO:0004954 | prostanoid receptor activity
Description: Combining with a prostanoid, any compound based on or derived from the prostanoate structure, to initiate a change in cell activity.
•
•
•
•
•
GO Term
GO:0072341 | modified amino acid binding
Description: Interacting selectively and non-covalently with a modified amino acid.
•
•
•
•
•
GO Term
GO:0001787 | natural killer cell proliferation
Description: The expansion of a natural killer cell population by cell division.
•
•
•
•
•
GO Term
GO:0001909 | leukocyte mediated cytotoxicity
Description: The directed killing of a target cell by a leukocyte.
•
•
•
•
•
GO Term
GO:0001788 | antibody-dependent cellular cytotoxicity
Description: Cytolysis of target cells by natural killer cells, eosinophils, neutrophils, monocytes, or macrophages following engagement of antibodies bound to the target cells by Fc receptors on the effector cells.
•
•
•
•
•
GO Term
GO:0001794 | type IIa hypersensitivity
Description: An inflammatory response resulting in cell death mediated by activation of the classical complement pathway or induction of effector cell phagocytosis or cytolysis mechanisms via complement or Fc receptors following the binding of antibodies to cell surface antigens on a target cell.
•
•
•
•
•
GO Term
GO:0002438 | acute inflammatory response to antigenic stimulus
Description: An acute inflammatory response to an antigenic stimulus. An acute inflammatory response occurs within a matter of minutes or hours, and either resolves within a few days or becomes a chronic inflammatory response.
•
•
•
•
•
GO Term
GO:0002437 | inflammatory response to antigenic stimulus
Description: An inflammatory response to an antigenic stimulus, which can be include any number of T cell or B cell epitopes.
•
•
•
•
•
GO Term
GO:0002445 | type II hypersensitivity
Description: An inflammatory response resulting in cell death or dysfunction mediated by activation of the classical complement pathway or induction of effector cell phagocytosis, cytolysis mechanisms via complement or Fc receptors following the binding of antibodies to cell surface antigens on a target cell, or mediated by the direct binding of antibody to cellular receptors.
•
•
•
•
•
GO Term
GO:0002444 | myeloid leukocyte mediated immunity
Description: Any process involved in the carrying out of an immune response by a myeloid leukocyte.
•
•
•
•
•
GO Term
GO:0002524 | hypersensitivity
Description: An inflammatory response to an exogenous environmental antigen or an endogenous antigen initiated by the adaptive immune system.
•
•
•
•
•
GO Term
GO:0001906 | cell killing
Description: Any process in an organism that results in the killing of its own cells or those of another organism, including in some cases the death of the other organism. Killing here refers to the induction of death in one cell by another cell, not cell-autonomous death due to internal or other environmental conditions.
•
•
•
•
•
GO Term
GO:0001790 | polymeric immunoglobulin binding
Description: Interacting selectively and non-covalently with a J-chain-containing polymeric immunoglobulin of the IgA or IgM isotypes.
•
•
•
•
•
GO Term
GO:0001791 | IgM binding
Description: Interacting selectively and non-covalently with an immunoglobulin of the IgM isotype.
•
•
•
•
•
GO Term
GO:0019763 | immunoglobulin receptor activity
Description: Combining with the Fc region of an immunoglobulin protein and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.
•
•
•
•
•
GO Term
GO:0001792 | polymeric immunoglobulin receptor activity
Description: Combining with a J-chain-containing polymeric immunoglobulin of the IgA or IgM isotypes via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.
•
•
•
•
•
GO Term
GO:0001793 | IgM receptor activity
Description: Combining with an immunoglobulin of the IgM isotype via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.
•
•
•
•
•
GO Term
GO:0001795 | type IIb hypersensitivity
Description: An inflammatory response resulting in cell death or dysfunction mediated by the direct binding of antibody to cellular receptors.
•
•
•
•
•
GO Term
GO:0001796 | regulation of type IIa hypersensitivity
Description: Any process that modulates the frequency, rate, or extent of type IIa hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0002892 | regulation of type II hypersensitivity
Description: Any process that modulates the frequency, rate, or extent of type II hypersensitivity.
•
•
•
•
•
GO Term
GO:0002883 | regulation of hypersensitivity
Description: Any process that modulates the frequency, rate, or extent of hypersensitivity.
•
•
•
•
•
GO Term
GO:0002861 | regulation of inflammatory response to antigenic stimulus
Description: Any process that modulates the frequency, rate, or extent of an inflammatory response to an antigenic stimulus.
•
•
•
•
•
GO Term
GO:0002886 | regulation of myeloid leukocyte mediated immunity
Description: Any process that modulates the frequency, rate, or extent of myeloid leukocyte mediated immunity.
•
•
•
•
•
GO Term
GO:0002864 | regulation of acute inflammatory response to antigenic stimulus
Description: Any process that modulates the frequency, rate, or extent of an acute inflammatory response to an antigenic stimulus.
•
•
•
•
•
GO Term
GO:0002822 | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
Description: Any process that modulates the frequency, rate, or extent of an adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains. An example of this process is found in the Gnathostomata.
•
•
•
•
•
GO Term
GO:0002889 | regulation of immunoglobulin mediated immune response
Description: Any process that modulates the frequency, rate, or extent of an immunoglobulin mediated immune response.
•
•
•
•
•
GO Term
GO:0002712 | regulation of B cell mediated immunity
Description: Any process that modulates the frequency, rate, or extent of B cell mediated immunity.
•
•
•
•
•
GO Term
GO:0002673 | regulation of acute inflammatory response
Description: Any process that modulates the frequency, rate, or extent of an acute inflammatory response.
•
•
•
•
•
GO Term
GO:0002893 | negative regulation of type II hypersensitivity
Description: Any process that stops, prevents, or reduces the frequency, rate, or extent of type II hypersensitivity.
•
•
•
•
•
GO Term
GO:0001797 | negative regulation of type IIa hypersensitivity
Description: Any process that stops, prevents, or reduces the rate of type IIa hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0002884 | negative regulation of hypersensitivity
Description: Any process that stops, prevents, or reduces the frequency, rate, or extent of hypersensitivity.
•
•
•
•
•
GO Term
GO:0002887 | negative regulation of myeloid leukocyte mediated immunity
Description: Any process that stops, prevents, or reduces the frequency, rate, or extent of myeloid leukocyte mediated immunity.
•
•
•
•
•
GO Term
GO:0002674 | negative regulation of acute inflammatory response
Description: Any process that stops, prevents, or reduces the frequency, rate, or extent of an acute inflammatory response.
•
•
•
•
•
GO Term
GO:0002713 | negative regulation of B cell mediated immunity
Description: Any process that stops, prevents, or reduces the frequency, rate, or extent of B cell mediated immunity.
•
•
•
•
•
GO Term
GO:0002704 | negative regulation of leukocyte mediated immunity
Description: Any process that stops, prevents, or reduces the frequency, rate, or extent of leukocyte mediated immunity.
•
•
•
•
•
GO Term
GO:0002707 | negative regulation of lymphocyte mediated immunity
Description: Any process that stops, prevents, or reduces the frequency, rate, or extent of lymphocyte mediated immunity.
•
•
•
•
•
GO Term
GO:0002862 | negative regulation of inflammatory response to antigenic stimulus
Description: Any process that stops, prevents, or reduces the frequency, rate, or extent of an inflammatory response to an antigenic stimulus.
•
•
•
•
•
GO Term
GO:0002865 | negative regulation of acute inflammatory response to antigenic stimulus
Description: Any process that stops, prevents, or reduces the frequency, rate, or extent of an acute inflammatory response to an antigenic stimulus.
•
•
•
•
•
GO Term
GO:0002820 | negative regulation of adaptive immune response
Description: Any process that stops, prevents, or reduces the frequency, rate, or extent of an adaptive immune response.
•
•
•
•
•
GO Term
GO:0002823 | negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
Description: Any process that stops, prevents, or reduces the frequency, rate, or extent of an adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains. An example of this process is found in the Gnathostomata.
•
•
•
•
•
GO Term
GO:0002698 | negative regulation of immune effector process
Description: Any process that stops, prevents, or reduces the frequency, rate, or extent of an immune effector process.
•
•
•
•
•
GO Term
GO:0002890 | negative regulation of immunoglobulin mediated immune response
Description: Any process that stops, prevents, or reduces the frequency, rate, or extent of an immunoglobulin mediated immune response.
•
•
•
•
•
GO Term
GO:0002894 | positive regulation of type II hypersensitivity
Description: Any process that activates or increases the frequency, rate, or extent of type II hypersensitivity.
•
•
•
•
•
GO Term
GO:0001798 | positive regulation of type IIa hypersensitivity
Description: Any process that activates or increases the frequency, rate or extent of type IIa hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0002885 | positive regulation of hypersensitivity
Description: Any process that activates or increases the frequency, rate, or extent of hypersensitivity.
•
•
•
•
•
GO Term
GO:0002888 | positive regulation of myeloid leukocyte mediated immunity
Description: Any process that activates or increases the frequency, rate, or extent of myeloid leukocyte mediated immunity.
•
•
•
•
•
GO Term
GO:0002714 | positive regulation of B cell mediated immunity
Description: Any process that activates or increases the frequency, rate, or extent of B cell mediated immunity.
•
•
•
•
•
GO Term
GO:0002675 | positive regulation of acute inflammatory response
Description: Any process that activates or increases the frequency, rate, or extent of an acute inflammatory response.
•
•
•
•
•
GO Term
GO:0002824 | positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
Description: Any process that activates or increases the frequency, rate, or extent of an adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains. An example of this process is found in the Gnathostomata.
•
•
•
•
•
GO Term
GO:0002863 | positive regulation of inflammatory response to antigenic stimulus
Description: Any process that activates or increases the frequency, rate, or extent of an inflammatory response to an antigenic stimulus.
•
•
•
•
•
GO Term
GO:0002866 | positive regulation of acute inflammatory response to antigenic stimulus
Description: Any process that activates or increases the frequency, rate, or extent of an acute inflammatory response to an antigenic stimulus.
•
•
•
•
•
GO Term
GO:0001799 | regulation of type IIb hypersensitivity
Description: Any process that modulates the frequency, rate, or extent of type IIb hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0001800 | negative regulation of type IIb hypersensitivity
Description: Any process that stops, prevents, or reduces the rate of type IIb hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0001801 | positive regulation of type IIb hypersensitivity
Description: Any process that activates or increases the frequency, rate or extent of type IIb hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0001802 | type III hypersensitivity
Description: An inflammatory response resulting from recognition of immune complexes via complement or Fc receptors on effector cells leading to activation of neutrophils and other leukocytes and damage to bystander tissue.
•
•
•
•
•
GO Term
GO:0001803 | regulation of type III hypersensitivity
Description: Any process that modulates the frequency, rate, or extent of type III hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0001804 | negative regulation of type III hypersensitivity
Description: Any process that stops, prevents, or reduces the rate of type III hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0001805 | positive regulation of type III hypersensitivity
Description: Any process that activates or increases the frequency, rate or extent of type III hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0001806 | type IV hypersensitivity
Description: An inflammatory response driven by T cell recognition of processed soluble or cell-associated antigens leading to cytokine release and leukocyte activation.
•
•
•
•
•
GO Term
GO:0002709 | regulation of T cell mediated immunity
Description: Any process that modulates the frequency, rate, or extent of T cell mediated immunity.
•
•
•
•
•
GO Term
GO:0001807 | regulation of type IV hypersensitivity
Description: Any process that modulates the frequency, rate, or extent of type IV hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0002710 | negative regulation of T cell mediated immunity
Description: Any process that stops, prevents, or reduces the frequency, rate, or extent of T cell mediated immunity.
•
•
•
•
•
GO Term
GO:0001808 | negative regulation of type IV hypersensitivity
Description: Any process that stops, prevents, or reduces the rate of type IV hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0001809 | positive regulation of type IV hypersensitivity
Description: Any process that activates or increases the frequency, rate or extent of type IV hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0002711 | positive regulation of T cell mediated immunity
Description: Any process that activates or increases the frequency, rate, or extent of T cell mediated immunity.
•
•
•
•
•
GO Term
GO:0001810 | regulation of type I hypersensitivity
Description: Any process that modulates the frequency, rate, or extent of type I hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0016068 | type I hypersensitivity
Description: An inflammatory response driven by antigen recognition by antibodies bound to Fc receptors on mast cells or basophils, occurring within minutes after exposure of a sensitized individual to the antigen, and leading to the release of a variety of inflammatory mediators such as histamines.
•
•
•
•
•
GO Term
GO:0001811 | negative regulation of type I hypersensitivity
Description: Any process that stops, prevents, or reduces the rate of type I hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0001812 | positive regulation of type I hypersensitivity
Description: Any process that activates or increases the frequency, rate or extent of type I hypersensitivity, a type of inflammatory response.
•
•
•
•
•
GO Term
GO:0001910 | regulation of leukocyte mediated cytotoxicity
Description: Any process that modulates the frequency, rate, or extent of leukocyte mediated cytotoxicity.
•
•
•
•
•
GO Term
GO:0001813 | regulation of antibody-dependent cellular cytotoxicity
Description: Any process that modulates the frequency, rate, or extent of antibody-dependent cellular cytotoxicity.
•
•
•
•
•
GO Term
GO:0031341 | regulation of cell killing
Description: Any process that modulates the frequency, rate or extent of cell killing, the process in which a cell brings about the death of another cell, either in the same or a different organism.
•
•
•
•
•
GO Term
GO:0001814 | negative regulation of antibody-dependent cellular cytotoxicity
Description: Any process that stops, prevents, or reduces the rate of antibody-dependent cellular cytotoxicity.
•
•
•
•
•
GO Term
GO:0001911 | negative regulation of leukocyte mediated cytotoxicity
Description: Any process that stops, prevents, or reduces the rate of leukocyte mediated cytotoxicity.
•
•
•
•
•
GO Term
GO:0001815 | positive regulation of antibody-dependent cellular cytotoxicity
Description: Any process that activates or increases the frequency, rate or extent of antibody-dependent cellular cytotoxicity.
•
•
•
•
•
GO Term
GO:0001912 | positive regulation of leukocyte mediated cytotoxicity
Description: Any process that activates or increases the frequency, rate or extent of leukocyte mediated cytotoxicity.
•
•
•
•
•
GO Term
GO:0031343 | positive regulation of cell killing
Description: Any process that activates or increases the frequency, rate or extent of cell killing.
•
•
•
•
•
GO Term
GO:0001818 | negative regulation of cytokine production
Description: Any process that stops, prevents, or reduces the rate of production of a cytokine.
•
•
•
•
•
GO Term
GO:0006837 | serotonin transport
Description: The directed movement of serotonin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Serotonin (5-hydroxytryptamine) is a monoamine neurotransmitter occurring in the peripheral and central nervous systems.
•
•
•
•
•
GO Term
GO:0001820 | serotonin secretion
Description: The regulated release of serotonin by a cell. Serotonin (5-hydroxytryptamine, or 5-HT) is a monoamine synthesised in serotonergic neurons in the central nervous system, enterochromaffin cells in the gastrointestinal tract and some immune system cells.
•
•
•
•
•
GO Term
GO:0015844 | monoamine transport
Description: The directed movement of monoamines, organic compounds that contain one amino group that is connected to an aromatic ring by an ethylene group (-CH2-CH2-), into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
•
•
•
•
•
GO Term
GO:0051608 | histamine transport
Description: The directed movement of histamine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Histamine is a physiologically active amine, found in plant and animal tissue and released from mast cells as part of an allergic reaction in humans.
•
•
•
•
•
GO Term
GO:0001821 | histamine secretion
Description: The regulated release of histamine by a cell or tissue. It is formed by decarboxylation of histidine and it acts through receptors in smooth muscle and in secretory systems.
•
•
•
•
•
GO Term
GO:0045117 | azole transport
Description: The directed movement of azoles, heterocyclic compounds found in many biologically important substances, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
•
•
•
•
•
GO Term
GO:0001824 | blastocyst development
Description: The process whose specific outcome is the progression of the blastocyst over time, from its formation to the mature structure. The mammalian blastocyst is a hollow ball of cells containing two cell types, the inner cell mass and the trophectoderm.
•
•
•
•
•
GO Term
GO:0001825 | blastocyst formation
Description: The initial formation of a blastocyst from a solid ball of cells known as a morula.
•
•
•
•
•
GO Term
GO:0001826 | inner cell mass cell differentiation
Description: The process in which a relatively unspecialized cell acquires specialized features of an inner cell mass cell.
•
•
•
•
•
GO Term
GO:0001827 | inner cell mass cell fate commitment
Description: The cell fate commitment of precursor cells that will become inner cell mass cells.
•
•
•
•
•
GO Term
GO:0001828 | inner cell mass cellular morphogenesis
Description: The morphogenesis of cells in the inner cell mass.
•
•
•
•
•
GO Term
GO:0001829 | trophectodermal cell differentiation
Description: The process in which a relatively unspecialized cell acquires the specialized features of a trophectoderm cell.
•
•
•
•
•
GO Term
GO:0001830 | trophectodermal cell fate commitment
Description: The cell fate commitment of precursor cells that will become trophectoderm cells.
•
•
•
•
•
USDA
InterMine logo
The Legume Information System (LIS) is a research project of the USDA-ARS:Corn Insects and Crop Genetics Research in Ames, IA.
LegumeMine || ArachisMine | CicerMine | GlycineMine | LensMine | LupinusMine | PhaseolusMine | VignaMine | MedicagoMine
InterMine © 2002 - 2022 Department of Genetics, University of Cambridge, Downing Street, Cambridge CB2 3EH, United Kingdom